Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 02 2022
Historique:
received: 19 10 2021
accepted: 13 01 2022
entrez: 17 2 2022
pubmed: 18 2 2022
medline: 9 3 2022
Statut: epublish

Résumé

A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profile among low- and high-grade adenomas and in situ carcinoma with detailed follow up. We have investigated the mutation spectrum of well-known genes involved in CRC (such as APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53) in a large, well-defined series of 96 adenomas and in situ carcinomas using a high-throughput genotyping technique. Besides, the microsatellite instability and APC and MLH1 promoter methylation were studied as well. We observed a high frequency of pathogenic variants in the studied genes. The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. Further, when we stratified mutation frequency based on the grade, the frequency distribution was as follows: low-grade adenoma-high-grade adenomas-in situ carcinoma: APC gene 42.9-56.0-54.5%; KRAS gene 32.7-32.0-45.5%; TP53 gene 8.2-20.0-18.2%. The occurrence of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter was significantly associated with the presence of POLE genetic variations. However, no association was noticed with the presence of any singular mutation and occurrence of subsequent adenoma or CRC. Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS.

Identifiants

pubmed: 35173208
doi: 10.1038/s41598-022-06498-9
pii: 10.1038/s41598-022-06498-9
pmc: PMC8850440
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2570

Commentaires et corrections

Type : ErratumIn
Type : ErratumIn

Informations de copyright

© 2022. The Author(s).

Références

Nature. 2019 Oct;574(7779):532-537
pubmed: 31645730
BMC Bioinformatics. 2014 Aug 29;15:293
pubmed: 25176396
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
PLoS One. 2013;8(1):e52501
pubmed: 23326336
Gastroenterology. 2015 Oct;149(5):1177-1190.e3
pubmed: 26216840
Genome Res. 2020 Jun;30(6):803-813
pubmed: 32661091
J Thorac Oncol. 2017 Apr;12(4):704-713
pubmed: 28007623
Hum Mutat. 2003 Jun;21(6):577-81
pubmed: 12754702
Cancer Res. 2002 Nov 15;62(22):6451-5
pubmed: 12438234
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Cancer Res. 2003 Aug 15;63(16):4878-81
pubmed: 12941809
Nat Genet. 2013 Feb;45(2):136-44
pubmed: 23263490
Virchows Arch. 2016 Aug;469(2):125-34
pubmed: 27325016
Hum Mutat. 2011 May;32(5):557-63
pubmed: 21520333
PLoS One. 2012;7(7):e41963
pubmed: 22848674
Nucleic Acids Res. 2017 Jul 27;45(13):7786-7795
pubmed: 28531315
Front Cell Dev Biol. 2021 May 24;9:660924
pubmed: 34150757
Mol Aspects Med. 2019 Oct;69:107-122
pubmed: 31189073
Oncol Rep. 2006 Dec;16(6):1245-52
pubmed: 17089045
Int J Mol Sci. 2020 May 05;21(9):
pubmed: 32380676
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Br J Cancer. 2019 Aug;121(4):344-350
pubmed: 31312029
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Mol Diagn Ther. 2013 Jun;17(3):193-203
pubmed: 23606169
Br J Cancer. 2017 Sep 5;117(6):1215-1223
pubmed: 28742792
Dig Dis Sci. 2015 Mar;60(3):762-72
pubmed: 25492499
Mutagenesis. 2021 Oct 6;36(5):358-368
pubmed: 34214148
Gut. 2000 Aug;47(2):251-5
pubmed: 10896917
Eur J Cancer. 2005 Jul;41(11):1649-54
pubmed: 15994075
Oncogene. 2013 Nov 14;32(46):5333-7
pubmed: 23246972
Int J Cancer. 2004 Sep 10;111(4):633-9
pubmed: 15239144
Genes Chromosomes Cancer. 2018 Jul;57(7):366-376
pubmed: 29575536
Nat Ecol Evol. 2018 Oct;2(10):1661-1672
pubmed: 30177804
Int J Mol Epidemiol Genet. 2013;4(1):1-10
pubmed: 23565319
Oncotarget. 2017 Jul 11;8(28):46468-46479
pubmed: 28515349
Nat Rev Cancer. 2016 Feb;16(2):71-81
pubmed: 26822575
BMC Med Genet. 2014 Jan 31;15:17
pubmed: 24484585

Auteurs

Jiri Jungwirth (J)

Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Department of Surgery, Weiden Clinic, Söllnerstraße 16, 92637, Weiden in der Oberpfalz, Germany.

Marketa Urbanova (M)

Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.

Arnoud Boot (A)

Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

Petr Hosek (P)

Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic.

Petra Bendova (P)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic.

Anna Siskova (A)

Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.

Jiri Svec (J)

Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic.
Department of Radiotherapy and Oncology, Third Faculty of Medicine, Charles University, Srobarova 50, 100 34, Prague 10, Czech Republic.

Milan Kment (M)

Second Department of Internal Medicine, Third Faculty of Medicine, Charles University, Srobarova 50, 100 34, Prague 10, Czech Republic.

Daniela Tumova (D)

DT Gastroenterology, Roskotova 1/1225, Prague 4, Czech Republic.

Sandra Summerova (S)

Department of Internal Medicine, Third Faculty of Medicine Charles University and Thomayer University Hospital, Ruska 87, 100 00, Prague, Czech Republic.

Zdenek Benes (Z)

Department of Internal Medicine, Third Faculty of Medicine Charles University and Thomayer University Hospital, Ruska 87, 100 00, Prague, Czech Republic.

Tomas Buchler (T)

Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic.

Pavel Kohout (P)

Department of Internal Medicine, Third Faculty of Medicine Charles University and Thomayer University Hospital, Ruska 87, 100 00, Prague, Czech Republic.

Tomas Hucl (T)

Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21, Prague, Czech Republic.

Radoslav Matej (R)

Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic.
Department of Pathology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague 10, Czech Republic.

Ludmila Vodickova (L)

Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic.

Tom van Wezel (T)

Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.

Pavel Vodicka (P)

Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.
Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic.

Veronika Vymetalkova (V)

Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic. veronika.vymetalkova@iem.cas.cz.
Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic. veronika.vymetalkova@iem.cas.cz.
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic. veronika.vymetalkova@iem.cas.cz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH